Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NEOS

Neos Therapeutics (NEOS) Stock Price, News & Analysis

Neos Therapeutics logo

About Neos Therapeutics Stock (NASDAQ:NEOS)

Advanced Chart

Key Stats

Today's Range
$1.06
$1.18
50-Day Range
$0.77
$1.18
52-Week Range
$0.45
$1.68
Volume
15.01 million shs
Average Volume
7.44 million shs
Market Capitalization
$57.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.

Receive NEOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NEOS Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
MCET MultiCell Technologies, Inc.
NEOS/USD - NeosCoin US Dollar
Cara Therapeutics, Inc. (CARA)
See More Headlines

NEOS Stock Analysis - Frequently Asked Questions

Neos Therapeutics, Inc. (NASDAQ:NEOS) issued its earnings results on Monday, November, 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05. The company had revenue of $12.54 million for the quarter.

Neos Therapeutics (NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neos Therapeutics investors own include TherapeuticsMD (TXMD), Onconova Therapeutics (ONTX), Adamis Pharmaceuticals (ADMP), Acasti Pharma (ACST), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP) and AVEO Pharmaceuticals (AVEO).

Company Calendar

Last Earnings
11/09/2020
Today
5/27/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NEOS
Fax
N/A
Employees
213
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.90 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$64.65 million
Price / Cash Flow
N/A
Book Value
($0.12) per share
Price / Book
-9.58

Miscellaneous

Free Float
N/A
Market Cap
$57.22 million
Optionable
Optionable
Beta
1.50
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:NEOS) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners